MedTrace Logo

Study to Enable New Diagnostics for Pulmonary Microbes in People With CF

NCT07312734 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-12-31

No results posted yet for this study

Summary

Sputum culture has been the best approach to detect harmful bacteria in the lungs of people with cystic fibrosis (CF). With the widespread use of new CF therapies (like Trikafta and Alyftrak), it is more difficult for people with CF to produce sputum even though they still have harmful bacteria in their lungs. The SEND-CF study is being done to see if there are other ways to detect harmful bacteria in the lungs.

Conditions

  • Cystic Fibrosis (CF)
  • New Diagnostics

Sponsors & Collaborators

Principal Investigators

  • Gina Hong, MD, MHS · University of Pennsylvania

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-01
Primary Completion
2027-08-01
Completion
2027-08-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07312734 on ClinicalTrials.gov